Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics Inc (TENX) is a clinical-stage pharmaceutical company developing therapies for cardiovascular and pulmonary diseases with high unmet needs. This page provides official updates on clinical trials, regulatory milestones, and corporate developments.
Investors and researchers will find a centralized repository of press releases and verified news related to Tenax's lead candidate levosimendan, including progress on the Phase 3 LEVEL study for PH-HFpEF. Track updates on intellectual property expansions, partnership announcements, and scientific presentations.
All content is curated to meet investor needs for timely, accurate information on drug development progress. Bookmark this page for direct access to primary source materials from Tenax Therapeutics, without promotional commentary or speculative analysis.
Tenax Therapeutics (Nasdaq: TENX) reported its Q1 2021 financial results and business updates, highlighting its merger with PHPrecisionMed Inc. This merger enhances its portfolio for pulmonary hypertension treatments, targeting over 70% of the market. The transition to an oral formulation of Levosimendan is underway, potentially improving patient convenience. R&D expenses surged to $22.4 million due to the acquisition, resulting in a net loss of $23.7 million, or $1.64 per share. As of March 31, 2021, cash reserves stand at $4.0 million, expected to sustain operations until Q3 2021.
Tenax Therapeutics, Inc. (Nasdaq: TENX) has released positive results from its Phase 2 HELP Study, evaluating levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study showed an 84% responder rate in the open-label phase, although levosimendan did not significantly reduce exercise-PCWP compared to placebo. Notably, it improved the six-minute walk distance by 29.3 meters compared to placebo (p=0.033). The publication emphasizes the need for further studies on levosimendan, which demonstrates potential as a treatment for this severe condition.
Tenax Therapeutics (Nasdaq: TENX) announces the voluntary retirements of Ronald R. Blanck, D.O., Gregory Pepin, and Chris A. Rallis from its Board of Directors, effective June 10, 2021. This decision is part of a Board refreshment program, introducing four new directors earlier this year. Dr. Blanck, who served since 2009, will be succeeded by Gerald Proehl as Chairman. The Board will be reduced from 12 to 9 members post-retirement. Tenax focuses on developing treatments for cardiovascular and pulmonary diseases and owns North American rights to levosimendan, aimed at addressing high unmet medical needs.
Tenax Therapeutics, Inc. (Nasdaq: TENX) reported its financial results for the year ended December 31, 2020, revealing a net loss of $9.9 million ($1.33 per share), up from $8.4 million ($1.35 per share) in 2019. Research and development expenses increased to $4.6 million from $3.5 million, while general and administrative expenses rose to $5.3 million from $5.1 million. The completion of the merger with PH Precision Medicine has expanded Tenax's pipeline, including the acquisition of oral formulation rights for Levosimendan. The company aims to advance its leading candidates into late-stage clinical trials.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced its presentation and virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The pre-recorded presentation will be available on-demand starting March 9 at 7:00 A.M. (EST) on their website, tenaxthera.com. Tenax focuses on developing therapeutics for cardio-pulmonary diseases, with rights to levosimendan and plans for a pivotal trial of imatinib. Both drugs target significant unmet medical needs in their respective areas.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced the appointment of four new board members: June Almenoff, MD, PhD, Michael Davidson, MD, Declan Doogan, MD, and Stuart Rich, MD. CEO Anthony DiTonno expressed enthusiasm for their expertise, which is seen as crucial for advancing the company’s two leading pipeline assets into late-stage clinical testing. These assets include a new formulation of imatinib for pulmonary arterial hypertension and an oral formulation of levosimendan, which has been in-licensed from Orion. The new board members bring extensive experience in biopharma and clinical development.
Tenax Therapeutics, Inc. (Nasdaq: TENX) is set to host an investor conference call on January 21, 2021, discussing its recent acquisition of PH Precision Med, focused on developing imatinib for pulmonary arterial hypertension. The company aims to advance a delayed-release oral formulation of imatinib into a pivotal trial via the 505(b)(2) pathway. Tenax specializes in products targeting cardiovascular and pulmonary diseases and has recently released Phase 2 clinical trial data for levosimendan in treating pulmonary hypertension associated with heart failure.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced its acquisition of PH Precision Med, a biotech firm developing imatinib for pulmonary arterial hypertension (PAH). Imatinib, now with Orphan Drug Designation from the FDA, is set to enhance Tenax's pipeline as a Phase 3 ready candidate. The company aims to advance a delayed-release oral formulation of imatinib to mitigate side effects. The acquisition includes stock issuances and appoints Dr. Stuart Rich as Chief Medical Officer, enhancing Tenax's expertise in pulmonary hypertension.
Tenax Therapeutics, Inc. (Nasdaq: TENX) reported its Q3 2020 financial results, revealing a net loss of $2.2 million, or $0.18 per share, stable compared to the previous year. R&D expenses increased slightly to $1.0 million, while G&A expenses decreased to $1.2 million. Cash reserves stood at $8.7 million, expected to fund operations through Q3 2021. The company is advancing its Phase 3 clinical development of levosimendan for pulmonary hypertension and heart failure, and an upcoming R&D webinar is set for November 18, 2020, to discuss recent trial data and updates.
Tenax Therapeutics (Nasdaq: TENX) announced data from the 24-hour open-label portion of the HELP Study, focusing on levosimendan for patients with pulmonary hypertension and heart failure. The study revealed that 36 out of 44 patients, about 85%, responded positively to a 24-hour infusion of levosimendan, showing a significant reduction in pulmonary capillary wedge pressure. These results will be presented at the AHA Scientific Sessions 2020, demonstrating support for the upcoming double-blind phase of the trial.